GRI Bio announced that it received notice on July 2, 2024 from The Nasdaq Stock Market that the Company regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq Capital Market, and that the scheduled hearing before the Hearings Panel has been canceled.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio Regains Compliance with Nasdaq
- GRI Bio’s GRI-0621 shows efficacy in published pulmonary fibrosis study
- GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
- GRI Bio to Present at the 8th Annual IPF Summit
- GRI Bio Announces Closing of $4.0 Million Public Offering